Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 1.00 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952059 | 1.00 | NLRP3 (1.00) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952390 | 0.89 | NLRP3 (0.81) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952442 | 0.89 | NLRP3 (0.80) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL25818822 | 0.89 | NLRP3 (0.80) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952054 | 0.88 | NLRP3 (0.79) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL30061337 | 0.88 | NLRP3 (0.79) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952369 | 0.88 | NLRP3 (0.79) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952057 | 0.88 | NLRP3 (0.79) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23925594 | 0.87 | NLRP3 (0.78) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952202 | 0.87 | NLRP3 (0.78) | NLRP3DHODHTSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135842-B1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-4135842-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115485026-A | Pyrazolo [1,2-D ] [1,2,4] triazin-2-yl-acetamides as NLRP3 inflammatory pathway inhibitors | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885DHODH 1822/4885TSHR 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.